Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FGEN - FIBROGEN INC

IEX Last Trade
0.5481
-0.002   -0.347%

Share volume: 4,547
Last Updated: Fri 27 Dec 2024 05:29:28 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.39%

PREVIOUS CLOSE
CHG
CHG%
$0.55
0.00
-0.35%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
36%
Profitability 43%
Dept financing 26%
Liquidity 37%
Performance 31%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.88%
1 Month
28.64%
3 Months
27.32%
6 Months
-52.51%
1 Year
-37.55%
2 Year
-96.81%
Key data
Stock price
$0.55
P/E Ratio 
-0.22
DAY RANGE
$0.55 - $0.62
EPS 
-$1.70
52 WEEK RANGE
$0.31 - $2.93
52 WEEK CHANGE
-$45.14
MARKET CAP 
36.707 M
YIELD 
N/A
SHARES OUTSTANDING 
100.401 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
2.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,722,935
AVERAGE 30 VOLUME 
$1,124,896
Company detail
CEO: Enrique A. Conterno
Region: US
Website: fibrogen.com
Employees: 570
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

FibroGen, Inc. discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan. Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor, is in Phase III.

Recent news